Goldman Sachs raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $621 from $617 and keeps a Buy rating on the shares. The company reported Q1 product revenue of $2.77B, roughly in-line with consensus, while noting a decline in Trikafta sales, including a $100M headwind in Russia due to an illegal copy product, the analyst tells investors in a research note. Goldman adds however that it remains focused on Vertex’s two recent launches – Alyftrek in cystic fibrosis, with revenue of $54M, and Journavx in acute pain, where Vertex expects revenue contribution in the second half of the year.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target lowered to $442 from $450 at Scotiabank
- Vertex Pharmaceuticals price target raised to $464 from $462 at Morgan Stanley
- Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong Market Penetration and Strategic Clinical Advancements
- Cautious Hold Rating for Vertex Pharmaceuticals Amid Mixed Performance and Future Challenges
- Vertex Pharmaceuticals price target raised to $423 from $420 at RBC Capital
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue